Biomedical literature, made navigable
Discover articles through diseases, drugs, treatments, interventions, clinical instruments, institutions and funders extracted from the BMJ open corpus.
An entity family is a category of extracted information. Choose one to browse its named entities and supporting articles.
Organisations named as supporting, sponsoring, or funding research.
5,089 articles · 9,137 mentionsInstitutionsUniversities, hospitals, research centres, networks, and public bodies.
11,350 articles · 22,378 mentionsDrugsNamed medicines, compounds, vaccines, and pharmacological agents.
10,506 articles · 58,393 mentionsDiseasesNamed diseases, disorders, syndromes, injuries, and health conditions.
23,712 articles · 125,551 mentionsTreatmentsClinical therapies and care approaches used to manage a condition.
7,227 articles · 16,644 mentionsInterventionsProgrammes, procedures, policies, and other actions being evaluated.
4,132 articles · 9,994 mentionsClinical instrumentsNamed questionnaires, scales, scores, indices, and other clinical outcome assessments.
945 articles · 1,957 mentionsChoose an entity to see the articles in which it was identified.
…o underwent bilateral orthotopic lung transplantation (BOLT) at Northwestern Memorial Hospital (Sep 2021-May 2025) after at least one cycle of ICI therapy. Pa…
…by cemiplimab 350 mg IV on Day 5, or single-agent chemotherapy (vinorelbine, gemcitabine, or docetaxel). The primary endpoint is overall su…
…t for patients resistant to immune checkpoint inhibitors (ICI). Ateganosine (THIO; 6-thio-2’-deoxyguanosine) is recognized by telomerase an…
…minary antitumor activity across broad cancer types.Conclusions AWT020 demonstrates a manageable safety profile and promising early an…
…sions These findings provide a rationale for the combination of STAR0602 and SOC therapy in the clinical setting for patients with recur…
…n PBMC.Methods Patients with recurrent/metastatic head and neck squamous cell carcinoma (HNSCC) were randomized to receive a heterologous prime-boost r…
…egy to overcome key limitations of CD3-directed bsAb therapy in solid tumors.Ethics Approval The study was approved by the IRB (Ethics Commi…
…d and neck squamous cell carcinoma (HNSCC), IMANs combined with nivolumab induced greater tumor cytotoxicity than CPI alone. Notably, IMA…
…relimab 360mg IV q3 weeks, domvanalimab 15mg/kg IV q3 weeks and etrumadenant 150mg PO daily. The primary endpoint was objective response rat…
…:62-68.Chapuis AG, Ragnarsson GB, Nguyen HN, et al. Transferred melanoma-specific CD8+ T cells persist, mediate tumor regression, and acquire cen…
…mab and chemotherapy. These findings highlight the potential of STK-012 to overcome key limitations of the next wave immunotherapies by…
…nd T cells results in enhanced target cell killing when mAb and bsAb are given together. These data provide further support for eval…